Hamilton Thorne to Preview the New IVOS II and Showcase

Hamilton Thorne to Preview the New IVOS II and Showcase
Ground-Breaking IMSI-STRICT(TM) Analysis Software at ASRM 2012 
At ASRM, Hamilton Thorne Will Also Promote Its Upcoming Webinar on
the "Benefits of Using Lasers in Clinical Applications to Improve
Outcomes in Assisted Reproduction" 
BEVERLY, MA and TORONTO -- (Marketwire) -- 10/22/12 --  Hamilton
Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision laser
devices and advanced image analysis systems for the fertility, stem
cell and developmental biology research markets, today announced that
the Company will be attending the American Society for Reproductive
Medicine (ASRM) 68th Annual Meeting taking place in San Diego, CA,
October 20-24, 2012. ASRM is the premier U.S. meeting on reproductive
medicine and an ideal showcase for Hamilton Thorne to preview the
Company's new IVOS II CASA system, as well as showcase its newly
launched IMSI-STRICT(TM) imaging analysis software. To learn more
about Hamilton Thorne's full line of fertility products, including
the new IVOS II unit and IMSI-STRICT(TM) imaging analysis software,
please visit the Company's booth # 607. 
Hamilton Thorne will unveil its next generation CASA system, IVOS II,
which is the industry-leading integrated visual optical system for
sperm analysis. The new IVOS II hardware upgrades are available
immediately and will feature a sleek new bezel design with the load
button conveniently located away from jog buttons for improved
ergonomics. The IVOS II will also include a stronger, faster, and
smoother stage motor with acceleration/deceleration options, which
reduces abrupt start and stop actions on the sample slide. The IVOS
II system will still include vital analysis for motile, progressively
motile and static sperm analysis, including actual number counted,
sample total, concentrations and percentages.  
In addition to the IVOS II, Hamilton Thorne will prominently feature
its popular new IMSI-STRICT(TM) imaging analysis software at ASRM
2012. IMSI-STRICT(TM) provides fertility clinicians with the ability
to select optimum sperm and thus improve outcomes during ICSI
procedures. IMSI-STRICT combines Tygerberg Strict Criteria with
motile sperm organelle morphology examination (MSOME), and provides
software-based categorization using head siz
e, head shape, mid-piece,
and number of vacuoles. Using these analyzed parameters, sperm are
assigned to one of three categories: normal, sub-normal or abnormal.
Current research in the field supports that STRICT Criteria provides
the best possible outcomes in fertility research, which has generated
a strong demand for the Company's recently launched IMSI-STRICT(TM)
product. 
"The ASRM annual meeting continues to be a strategic launching pad
for several of our premier products such as the cutting-edge LYKOS(R)
clinical laser introduced in 2011 and our new IMSI-STRICT(TM)
analysis software; therefore it was a natural choice for us to
preview the next generation IVOS system at this prestigious fertility
event," said David Wolf, President and Chief Executive Officer of
Hamilton Thorne Ltd. "With its sleeker design, faster, smoother stage
and more powerful processor, the IVOS II hardware provides a greater
ease-of-use for our customers and is fully compatible with our
Version 14 software. In addition, the IVOS II will support future
software upgrades as we continue our commitment to this important
product line and build out additional capabilities."  
Also at ASRM 2012, Hamilton Thorne will be promoting an exciting free
Webinar entitled, "Benefits of Using Lasers in Clinical Applications
and an In-depth Discussion on Vitrification in Assisted
Reproduction." The Webinar will feature guest speaker Dr. Juergen
Liebermann, Laboratory Director of FCI's Chicago/River North IVF Lab,
and will take place on Tuesday, November 13th, 2012 at 11:00 AM EST.
The Webinar discussion will highlight Hamilton Thorne's infrared
laser technology and how it can benefit clinical applications such as
assisted hatching and blastomere/trophectoderm biopsy for
pre-implantation Genetic Diagnosis (PGD). A special focus of the
Webinar discussion will be dedicated to the work and research of Dr.
Juergen Liebermann, who will share his laboratory's results on how
Hamilton Thorne lasers can be successfully used to improve the embryo
vitrification process. 
If you are interested in attending the Webinar, please click on this
link to view the formal invitation and register for the online event:
http://www.hamiltonthorne.com/news/webinars.htm. 
In addition, Webinar guest speaker Dr. Liebermann will be presenting
an oral session at ASRM on Wednesday, October 24, 2012 at 12:30 PM
entitled, "Cryopreservation and Frozen Embryo Transfer in A.R.T.: Is
There Any Benefit in Artificial Collapse of Human Blastocysts Prior
to Vitrification?" The presentation will be given in room #8.  
About Hamilton Thorne Ltd. (www.hamiltonthorne.com)  
Hamilton Thorne designs, manufactures and distributes precision laser
devices and advanced image analysis systems for the fertility, stem
cell and development biology research markets. It provides novel
solutions for Life Science that reduce cost, increase productivity,
improve results and enable research breakthroughs in fertility,
regenerative medicine, and stem cell research markets. Hamilton
Thorne's laser products attach to standard inverted microscopes and
operate as robotic micro-surgeons, enabling a wide array of
scientific applications and IVF procedures. Its imaging systems
improve outcomes in human IVF clinics and animal breeding facilities
and provide high-end toxicology analyses.  
Hamilton Thorne was ranked in the 'Top 20' of the "Area's Largest
Medical Device Companies" by the Boston Business Journal in October
2012. The Company's growing customer base includes pharmaceutical
companies, biotechnology companies, fertility clinics, university
research centers, and other commercial and academic research
establishments worldwide. Current customers include world-leading
research labs such as Harvard, MIT, Yale, McGill, DuPont, Monsanto,
Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, and Oxford
and Cambridge. 
Neither the Toronto Venture Exchange, nor its regulation services
provider (as that term is defined in the policies of the exchange),
accepts responsibility for the adequacy or accuracy of this release.  
Certain information in this press release may contain forward-looking
statements. This information is based on current expectations that
are subject to significant risks and uncertainties that are difficult
to predict. Actual results might differ materially from results
suggested in any forward-looking statements. The Company assumes no
obligation to update the forward-looking statements, or to update the
reasons why actual results could differ from those reflected in the
forward-looking statements unless and until required by securities
laws applicable to the Company. Additional information identifying
risks and uncertainties is contained in filings by the Company with
the Canadian securities regulators, which filings are available at
www.sedar.com.  
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2127838 
For more information, please contact: 
David Wolf
President & CEO
Hamilton Thorne Ltd.
978-921-2050
ir@hamiltonthorne.com  
Lisa Rivero
Director of Corporate Communications
Hamilton Thorne Ltd.
978-921-2050
ir@hamiltonthorne.com